Given the large changes in Oat2 expression, the inhibitory potential of metabolites (adipate, suberate, glycolate, citrate, 3-hydroxyisobutyrate, cis-aconitate, and homovanillate) associated with diabetic kidney disease [26, 27], drugs for treatment of diabetes (sitagliptin, miglitol), and hypertension (captopril, enalapril, furosemide, and bumetanide) on human OAT2 expressed in HEK293 cells was investigated. Here, SLC22A7 is linked to diabetes mellitus.